找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: HCV: The Journey from Discovery to a Cure; Volume I Michael J. Sofia Book 2019 Springer Nature Switzerland AG 2019 HCV genome.Molecular Vir

[复制链接]
楼主: 喝水
发表于 2025-3-30 09:00:40 | 显示全部楼层
The Role of Interferon for the Treatment of Chronic Hepatitis C Virus InfectionN-α). While this reduced the need for subcutaneous injections from three times a week to once a week which improved patients’ adherence, the increase in SVR with PegIFN-α over standard IFN-α was relatively modest. Further, drug-related side effects remained problematic, limiting HCV treatment uptake
发表于 2025-3-30 16:17:53 | 显示全部楼层
发表于 2025-3-30 17:35:59 | 显示全部楼层
Discovery of Beclabuvir: A Potent Allosteric Inhibitor of the Hepatitis C Virus Polymerasemplex inhibitor daclatasvir and the NS3 protease inhibitor asunaprevir in a single, fixed-dose formulation (Ximency) resulted in the approval by the Japanese Pharmaceutical and Food Safety Bureau for its use in the treatment of patients infected with genotype 1 HCV.
发表于 2025-3-31 00:12:22 | 显示全部楼层
发表于 2025-3-31 04:04:14 | 显示全部楼层
发表于 2025-3-31 08:04:19 | 显示全部楼层
Discovery of Boceprevir, a Ketoamide-Derived HCV NS3 Protease Inhibitor, for Treatment of Genotype 1e compound libraries did not result in any starting point for SAR optimization. Introduction of electrophilic traps to natural substrate of the enzyme identified a ketoamide-derived undecapeptide lead. It was optimized to identify the first ketoamide-derived direct-acting antiviral agent for the tre
发表于 2025-3-31 09:47:21 | 显示全部楼层
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-5-11 10:05
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表